LATEST NEWS
Liquid biopsy: may ctDNA tumour fraction help interpret negative results?
A study illustrates a methodology that shows promise to distinguish true negative liquid biopsy results from indeterminate results that may benefit from follow-up tissue testing
Early breast cancer: higher quality of life reported with a personalised follow-up
A nurse-led follow-up strategy including self-management interventions, use of patient-reported outcomes and phone consultations also resulted in lower fear of recurrence, anxiety and depression
Are ADCs in lung cancer living up to expectations?
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
COLUMNS
How much ‘green’ is cancer research?
Clinical trials have an impact on the environment, and novel approaches may help researchers reshape their activities toward a greater sustainability
Health as a human right, cancer care as a human priority
Universal health coverage in oncology is still not a reality, as a recent report shows
Use of ctDNA as a surrogate in early clinical drug development – nearing its end point?
Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed
ROAD TO ESMO GASTROINTESTINAL CANCERS CONGRESS 2024
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
Colorectal cancer screening: performance of a blood-based test is promising
A study reports high sensitivity and specificity of a cell-free DNA blood-based assay compared to colonoscopy